๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Doncaster
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Doncaster, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2853 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 25 Sep 2026, 03:15 UTC
2853
Studies in scope
industry-sponsored, all four open statuses
1387
Recruiting now
open to new participants
544
Lead sponsors
across recruiting studies
Top sites
London 2012 Manchester 669 Birmingham 470 Glasgow 439 Cambridge 418
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Trials with a site in Doncaster

23 of 2853 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
UK PureWickโ„ข At-Home Pilot Study
NCT07555548Urinary Incontinence
Becton, Dickinson and Company
Observational
95
Doncaster, Leicester, Northampton, Norwich
2026-05-06
Recruiting
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181Systemic Lupus Erythematosus
Boehringer Ingelheim
Phase 2
405
Basingstoke, Belfast, Cambridge, Doncaster, London
2026-04-20
Recruiting
A Study of Brenipatide in Participants With Opioid Use Disorder
NCT07420283Opioid Use Disorder
Eli Lilly and Company
Phase 2
465
Chertsey, Doncaster, Eastbourne, Glasgow, London, Manchester, Milton Keynes, Southampton
2026-02-13
Recruiting
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders
DrugCYB003
Cybin IRL Limited
Phase 3
330
Cambridge, Doncaster, Edinburgh, Glasgow, London, Newcastle upon Tyne, Reading, Sheffield
2025-12-10
Recruiting
A Study of Brenipatide in Participants With Alcohol Use Disorder
NCT07219953Alcohol Use Disorder
Eli Lilly and Company
Phase 3
1,100
Blackpool, Doncaster, Eastbourne, Glasgow, Hayle, Hounslow, London, Newquay
2025-10-16
Recruiting
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT07204275Primary Membranous Nephropathy
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Derby, Doncaster, Edinburgh, London, Wolverhampton
2025-09-30
Recruiting
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
NCT06524830Treatment Resistant Depression
atai Therapeutics, Inc.
Phase 2
142
Doncaster, London, Motherwell
2024-12-30
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
Janssen Research & Development, LLC
Phase 3
655
Cambridge, Doncaster, Greater London, Leeds, Liverpool, London, Peterborough, Swindon
2024-12-04
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801Crohn's Disease
Merck Sharp & Dohme LLC
Phase 3
1,200
Cambridge, Exeter, Doncaster, Huddersfield, London, Southampton, Oxford, Bristol
2024-06-05
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
Alexion Pharmaceuticals, Inc.
Phase 3
579
Cambridge, Doncaster, Leicester, London, Manchester, Reading, Stevenage
2024-03-29
Active, closed
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915Sjogrens Syndrome
Novartis Pharmaceuticals
Phase 3
612
Doncaster, Leeds, Liverpool, Newcastle upon Tyne, Swindon
2023-10-27
Active, closed
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059Ulcerative Colitis
Merck Sharp & Dohme LLC
Phase 3
1,020
Bristol, Cambridge, Exeter, Doncaster, Huddersfield, London, Southampton, West Midlands
2023-10-25
Active, closed
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
NCT05624749Systemic Lupus Erythematosus
Novartis Pharmaceuticals
Phase 3
288
Leeds, Doncaster
2023-04-21
Active, closed
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034Ischemic Stroke; Ischemic Attack, Transient
Janssen Research & Development, LLC
Phase 3
12,523
Aberdeen, Airdrie, Bath, Bury, Cheltenham, Dartford, Doncaster, Dundee
2023-02-15
Active, closed
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
NCT05711940Treatment Resistant Depression
COMPASS Pathways
Phase 3
572
Bodmin, Chertsey, Chester, Doncaster, Exeter, Fulbourn, London, Newcastle
2023-02-14
Active, closed
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
NCT05349214Sjogren Syndrome
Novartis Pharmaceuticals
Phase 3
506
Doncaster, Leeds, Liverpool, Newcastle upon Tyne, Swindon
2022-08-04
By invitation
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
NCT05352919Systemic Lupus Erythematosus (SLE)
Biogen
Phase 3
864
London, Doncaster, Cannock
2022-06-10
Active, closed
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04961567Lupus Erythematosus, Systemic
Biogen
Phase 3
562
London, Doncaster, Cannock
2021-07-16
Active, closed
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
NCT04877691Systemic Lupus Erythematosus
AstraZeneca
Phase 3
367
Doncaster, Leeds, London
2021-06-08
Active, closed
Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis
NCT04871919Rheumatoid Arthritis
Alfasigma S.p.A.
Observational
1,304
Aberdeen, Barnet, Coventry, Doncaster, Dundee, Edinburgh, Liverpool, London
2021-05-11
Active, closed
Clinical Study of Bone Graft Substitutes in Orthopaedic and Spinal Applications.
NCT03570606Bone Deformity
Ceramisys Ltd
Observational
220
Doncaster, Birmingham, North Shields, Salford, Stoke-on-Trent, Taunton
2019-06-13
Rows per page Showing 1–23 of 23
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-uk/city/doncaster

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,853 studies in total at the last sync on 25 Sep 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 23 of those studies with a site in Doncaster.

How many clinical trials are recruiting in Doncaster?

10 of the 23 studies on this page are recruiting new participants as of the 25 Sep 2026, 03:15 UTC sync. A further 0 have not yet opened recruitment, 12 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Doncaster), 23 studies
PhaseStudiesRecruitingShare
Phase 315465.2%
Phase 24417.4%
Observational3113%
Phase 2/3114.3%

Most active sponsors

Lead sponsors with the most studies (Doncaster)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals30
Biogen20
Eli Lilly and Company22
Janssen Research & Development, LLC20
Merck Sharp & Dohme LLC21
Alexion Pharmaceuticals, Inc.10
Alfasigma S.p.A.10
AstraZeneca10
atai Therapeutics, Inc.11
Becton, Dickinson and Company11
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.